Joel Ray

Nov 14, 2024 | jamanetwork.com | Ziv Harel |Nivethika Jeyakumar |Graham Smith |Joel Ray

Introduction Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are increasingly used to treat diabetes, heart failure, and chronic kidney disease.1 Approximately 80% of individuals taking SGLT2is also receive statins.2 A 2020 case report3 described the onset of rhabdomyolysis after initiation of canagliflozin in a patient taking rosuvastatin.

Nov 20, 2023 | cmaj.ca | Catherine Varner |Joel Ray

In this issue of CMAJ, Jain and colleagues argue for multifactorial screening for people at risk of early-onset preeclampsia, and acetylsalicylic acid (ASA) initiation for those who screen positive.1 Multifactorial screening at about 12 weeks’ gestation calculates risk according to clinical risk factors and results of uterine artery ultrasonography and biochemical testing.